Krystal Biotech, Inc.
KRYSNASDAQHealthcare● Active
$302.30
+$1.30(+0.43%)
Market Cap$8.9B
P/E Ratio—
52W High$319.48
52W Low$127.99
Krystal Biotech, Inc. (KRYS) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KRYS · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.39B | $0.29B | $0.05B | $0.00B | $0.00B |
| Cost of Revenue | $0.03B | $0.02B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.36B | $0.27B | $0.05B | $0.00B | $0.00B |
| Gross Margin %(computed) | 92.61% | 93.09% | 93.90% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.06B | $0.05B | $0.05B | $0.04B | $0.03B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.08B | $0.04B |
| Total Operating Expenses | $0.20B | $0.20B | $0.16B | $0.15B | $0.07B |
| Operating Income | $0.16B | $0.07B | ($0.11B) | ($0.15B) | ($0.07B) |
| Operating Margin %(computed) | 41.45% | 22.61% | -216.43% | — | — |
| Interest Income | $0.03B | $0.03B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.19B | $0.10B | $0.01B | ($0.14B) | ($0.07B) |
| Income Tax Expense | ($0.02B) | $0.01B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.20B | $0.09B | $0.01B | ($0.14B) | ($0.07B) |
| Net Margin %(computed) | 52.64% | 30.69% | 21.56% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $7.08 | $3.12 | $0.40 | $-5.49 | $-3.13 |
| Wtd Avg Shares | 0.03B | 0.03B | 0.03B | 0.03B | 0.02B |
| EBITDA | $0.17B | $0.11B | ($0.09B) | ($0.12B) | ($0.07B) |
| EBITDA Margin %(computed) | 43.13% | 37.83% | -180.11% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Krystal Biotech, Inc. data
About Krystal Biotech, Inc. (KRYS) Income Statement
Krystal Biotech, Inc. (KRYS) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, KRYS reported revenue of $0.39B, gross profit of $0.36B (gross margin 92.61%), and net income of $0.20B — a net profit margin of 52.64%.
Frequently asked questions
KRYS · 4 questionsKrystal Biotech, Inc. (KRYS) reported revenue of $0.39B for 2025, up 33.9% year-over-year.
KRYS revenueKRYS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08